Athersys

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.
Company Growth (employees)
Type
Public
HQ
Cleveland, US
Founded
1995
Size (employees)
60 (est)
Athersys was founded in 1995 and is headquartered in Cleveland, US

Key People at Athersys

Gil Van Bokkelen

Gil Van Bokkelen

Chairman & CEO
William Lehmann Jr

William Lehmann Jr

President, COO
John Harrington

John Harrington

Executive Vice President and Chief Scientific Officer
Laura Campbell

Laura Campbell

Controller
Manal Morsy

Manal Morsy

Vice President, Global Regulatory Affairs

Athersys Office Locations

Athersys has offices in Cleveland, Canton
Cleveland, US (HQ)
3201 Carnegie Ave
Canton, US
250 Royall St

Athersys Metrics

Athersys Financial Metrics

Revenue (2016)

$17.3 m

Revenue growth (2015-16), %

45%

Net income (2016)

($15.3 m)

Market capitalization (21-Mar-2017)

$126.3 m

Closing share price (21-Mar-2017)

$1.1

Cash (31-Dec-2016)

$14.8 m
Athersys's current market capitalization is $126.3 m.
Athersys's revenue was reported to be $17.3 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$2.4 m$1.6 m$11.9 m$17.3 m

Revenue growth, %

(33%)636%45%

Operating expense total

$26.9 m$30.6 m$29.1 m$33.1 m

EBIT

($24.5 m)($29 m)($17.2 m)($15 m)

EBIT margin, %

(1003%)(1788%)(144%)(87%)

Pre tax profit

($22.3 m)($16.5 m)($15.4 m)

Income tax expense

$253 k$38 k$37 k

Net Income

($30.7 m)($22.1 m)($16.4 m)($15.3 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$31.9 m$26.1 m$23 m$14.8 m

Accounts Receivable

$520 k$694 k$361 k$598 k

Inventories

Current Assets

$32.9 m$27.2 m$23.8 m$16.3 m

Total Assets

$34.2 m$28.7 m$25.1 m$19.1 m

Accounts Payable

$2.2 m$2.8 m$2.7 m$4.8 m

Current Liabilities

$4.4 m$4.7 m$4.8 m$6.9 m

Additional Paid-in Capital

$284.3 m$307.3 m$322.6 m$329.4 m

Retained Earnings

($264.4 m)($286.5 m)($302.9 m)($318.3 m)

Total Equity

$19.8 m$20.9 m$19.7 m$11.2 m

Financial Leverage

1.7 x1.4 x1.3 x1.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($30.7 m)($22.1 m)($16.4 m)($15.3 m)

Depreciation and Amortization

$346 k$360 k$267 k$382 k

Accounts Receivable

($30 k)($174 k)$333 k($237 k)

Inventories

Accounts Payable

($196 k)$335 k($296 k)$2.4 m

Cash From Operating Activities

($22.8 m)($25.8 m)($13.8 m)($10.9 m)

Cash From Investing Activities

($385 k)($297 k)($132 k)($1.1 m)

Athersys Market Value History

Athersys Online Presence

Athersys Company Life

You may also be interested in